Cardiac allograft vasculopathy is a common complication affecting heart transplant patients.
This condition causes narrowing of the heart arteries leading to graft dysfunction. The
research team is investigating whether early antiplatelet therapy post heart transplant can
prevent the development of CAV. This study will determine the feasibility of a large
multicenter randomized placebo-controlled trial to answer this question.